Qingsong Capital
清松资本
Qingsong Capital (清松资本) is a Chinese venture capital firm active in healthcare and deep-tech investing, though elsewhere's corpus does not contain a direct profile of the fund itself. The available material shows it operating primarily as a co-investor and follow-on investor in biotech and surgical robotics deals between 2021 and 2026.
Per the record, Qingsong Capital co-led the Series C in CDMO firm IntellectiveBio (智享生物) alongside Gaorong Capital in August 2022 , and joined a nearly 500 million yuan round for CasCade Therapeutics in February 2026 . It also made multiple follow-on investments in Cornerstone Robotics (康诺思腾), a surgical robot developer, across funding rounds in late 2021 and mid-2023 . In each case it appeared alongside established healthcare-focused peers such as Gaorong, Qiming Venture Partners, and Lilly Asia Ventures.
Elsewhere's corpus does not cover Qingsong Capital's founding date, fund size, or full team.
AI-generated — may contain errors, please verify.
Coverage
Rushi Robotics Closes 100 Million Yuan Pre-A Round to Build Embodied Intelligence Platform for Real-World Elder Care Scenarios | Tongcheng Family
Recently, **Dalton Venture portfolio company Shanghai Rushen Robotics Technology Co., Ltd.** (hereinafter referred to as "Rushen Robotics") **announced the completion of a 100-million-yuan Pre-A funding round**, with investment from Qingsong Capital, leading listed computing power company Range Intelligent Computing Technology, and Pinghu Zexin. This round of financing will strongly support Rushen Robotics' continuous operation in real elderly care scenarios, data generation, and model iteration. This follows Dalton Venture's sole investment in Rushen Robotics in September 2025
Two rounds in six months: Datong Capital continues to double down as Gestalt Technology closes a 420 million yuan angel+ round | Datong Family --- Gestalt Technology (格式塔科技) has completed a 420 million yuan angel+ financing round, with existing investor Datong Capital (道彤资本) leading the round. This marks Datong's second consecutive investment in the company within six months, following its participation in Gestalt's angel round earlier this year.
On July 3, 2026, **Gestala**, a **Daotong Family portfolio company** and China's first company focused on ultrasound-based brain-computer interfaces, announced the completion of a **420 million RMB angel+ funding round**, while simultaneously holding an inauguration ceremony for its Shanghai headquarters — establishing a dual-headquarters strategic layout across "Chengdu + Shanghai".
CasCade Therapeutics Closes Nearly 500 Million Yuan Major Funding Round, Targeting Nuclear Receptor and GPCR Innovative Drug R&D
Dedicated to becoming a global leader in metabolic disease therapeutics.
Cornerstone Robotics Completes New Funding Round, Accelerating Global Expansion of High-Quality Chinese Surgical Robots
Where surgery brings peace of mind, life unfolds in all its vastness.
We Analyzed 1,000 LP Commitments and Found 30 Hidden Top Family Offices
They are also a microcosm of China's commercial evolution.
Multiple Innovative Companies Gain Global Recognition, Breakthroughs Achieved in Computational Biology, LiDAR, and Other Fields | Rongbao · July
Major events in July.
CDMO firm ZhiXiang Biologics raises over 500 million yuan in Series C funding to accelerate biopharma R&D for global clients
A one-stop CDMO platform for biologics R&D and manufacturing.
Rongbao · November | New milestones for drug R&D, chips, and autonomous driving; UJU Media lists on Hong Kong Stock Exchange Main Board
New funding, new products, new applications.
Cornerstone Robotics, a Leader in Innovative Surgical Robot Technology, Closes RMB 500 Million Series B Funding Round
We have completed a multi-pipeline layout covering soft-tissue surgical robots and other major specialty surgical robots.
